Mitra Jelvehgari
1,2*, Seyed Hassan Montazam
3, Saieede Soltani
1, Rahil mohammadi
2, Karim Azar
4, Seyed Ataollah Montazam
51 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Microbiology, Bonab Branch, Islamic Azad University, Bonab, Iran
4 Health & Bioscience Department, London Brunel University, London, UK.
5 Student Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran
Abstract
Ergotamine
tartrate (ET), a serotonin 5-HT1 receptor agonist, is an anti-migraine drug. Due to high first-pass metabolism, ET shows a very low
bioavailability in oral administrations (<1%). Caffeine (CA)
increases the rate and extent of water solubility of ET. The present study
intended to investigate the possibility of developing ET fast dissolving thin
films for the fast drug dissolution in the oral cavity, and thus bypassing
first pass metabolism for providing quick onset of action of the drug. Methods:
The films (ET and CA) were prepared according to solvent casting method,
separately. Low viscosity grade of hydroxylpropyl methylcellulose (HPMC E-15)
was employed in preparation as a film forming polymer. Propylene glycol was the
plasticizer used. All the films were evaluated for their thickness, weight
variations, folding endurance, surface pH, disintegration, drug content, DSC,
in-vitro drug release, and ex-vivo permeation. Results: The best
polymer drug ratio in ET/CA films was 1:20 (E2) and 1:4 (C2),
respectively. The films E2 and C2 showed 9.9, 3.2 mg
weight, 74, 45 µm thickness, 120.66, up to 300 folding endurance and 0.38, 0.52
mg/cm2 drug content, respectively. The DSC showed no
stable characteristic for ET and CA in the drug loaded films and revealed amorphous form. The results showed that ET films
prepared had faster release and CA films had slower release (p<o.o5).
Both films (ET and CA) exhibited good mucoadhesion properties and shorter
retention time (36-150 s). Conclusion: The formulations were
found to be a suitable candidate for the development of oral thin films for
migraine therapy.